

Matteo Santoni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1120416/matteo-santoni-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

245
papers

5,107
citations

40
h-index

56
g-index

282
ext. papers

6,443
ext. citations

5.1
avg, IF

5.62
L-index

#	Paper	IF	Citations
245	Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.. <i>Future Oncology</i> , 2022 ,	3.6	2
244	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 170, 103596	7	0
243	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.. <i>European Urology Focus</i> , 2022 ,	5.1	2
242	Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study.. <i>European Urology</i> , 2022 ,	10.2	0
241	Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis.. <i>Tumori</i> , 2022 , 3008916221090323	1.7	
240	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT.. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
239	Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. <i>European Urology Focus</i> , 2021 ,	5.1	17
238	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. <i>Translational Andrology and Urology</i> , 2021 , 10, 1562-1568	2.3	1
237	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. <i>Translational Andrology and Urology</i> , 2021 , 10, 1530-1540	2.3	0
236	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?-a narrative review. <i>Translational Andrology and Urology</i> , 2021 , 10, 1541-1552	2.3	2
235	Agent-Based Learning Model for the Obesity Paradox in RCC. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021 , 9, 642760	5.8	1
234	Knock-Down of Mucolipin 1 Channel Promotes Tumor Progression and Invasion in Human Glioblastoma Cell Lines. <i>Frontiers in Oncology</i> , 2021 , 11, 578928	5.3	4
233	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
232	Impact of clinicopathological features on survival in patients treated with immune-based combinations for metastatic urothelial carcinoma: A meta-analysis of randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16534-e16534	2.2	
231	Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. <i>Immunotherapy</i> , 2021 , 13, 783-793	3.8	0
230	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , 2021 , 26, 740-750	5.7	3
229	The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5

228	Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. <i>European Urology</i> , 2021 , 79, 887-889	10.2	1
227	Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. <i>Pathology Research and Practice</i> , 2021 , 222, 153440	3.4	4
226	Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 1-7	2.2	4
225	Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review. <i>Future Oncology</i> , 2021 , 17, 2671-2681	3.6	2
224	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e84-e91	3.3	11
223	Gut microbiota, immunity and pain. <i>Immunology Letters</i> , 2021 , 229, 44-47	4.1	6
222	Predicting future cancer burden in the United States by artificial neural networks. <i>Future Oncology</i> , 2021 , 17, 159-168	3.6	6
221	Treating Prostate Cancer by Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	8
220	An update on investigational therapies that target STAT3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 245-251	5.9	3
219	Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 1237-1243	5.5	1
218	A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. <i>Anti-Cancer Drugs</i> , 2021 ,	2.4	1
217	Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 1029-1054	3.5	4
216	Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1876, 188547	11.2	4
215	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021 , 16, 625-632	5	2
214	An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 2323-2336	4	1
213	Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021 , 154, 120-127	7.5	22
212	Microbiota and prostate cancer. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	5
211	The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors. <i>Diagnostics</i> , 2021 , 11,	3.8	5

210	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. <i>Diagnostics</i> , 2021 , 11,	3.8	5
209	Involvement of the TRPML Mucolipin Channels in Viral Infections and Anti-viral Innate Immune Responses. <i>Frontiers in Immunology</i> , 2020 , 11, 739	8.4	10
208	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 491-501	3.5	6
207	Emerging Role of Mucolipins TRPML Channels in Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 659	5.3	14
206	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	38
205	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
204	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. <i>Cells</i> , 2020 , 9,	7.9	2
203	Renal Cell Carcinoma: genomic landscape and clinical implications. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020 , 5, 95-100	1.6	1
202	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS762-TPS762	2.2	
201	Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS596-TPS596	2.2	
200	Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020 , 21, 416-423	3	4
199	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020 , 21, 1463-1475	3.5	4
198	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020 , 21, 1664-1671	3	3
197	Staging and Reporting of Renal Cell Carcinomas 2020 , 423-436		
196	Baseline and early change of neutrophil to lymphocyte ratio (bNLR and nNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17081-e17081	2.2	
195	The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions. <i>Journal of Thoracic Disease</i> , 2020 , 12, 7245-7256	2.6	
194	Calcium Signaling and the Regulation of Chemosensitivity in Cancer Cells: Role of the Transient Receptor Potential Channels. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1131, 505-517	3.6	10
193	Designing novel immunocombinations in metastatic renal cell carcinoma. <i>Immunotherapy</i> , 2020 , 12, 1257-1268	3.4	4

192	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020 , 15, 495-501	5	12
191	Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ERHER2Rb wild-type and knock-down in breast cancer cell lines. <i>BMC Cancer</i> , 2020 , 20, 1119	4.8	3
190	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020 , 9,	7.9	25
189	Exploring the Spectrum of Kidney Ciliopathies. <i>Diagnostics</i> , 2020 , 10,	3.8	1
188	The TRPV2 cation channels: from urothelial cancer invasiveness to glioblastoma multiforme interactome signature. <i>Laboratory Investigation</i> , 2020 , 100, 186-198	5.9	17
187	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 207-217	3.8	4
186	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 141-150	3.8	9
185	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , 2019 , 11,	6.6	11
184	Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications. <i>BioDrugs</i> , 2019 , 33, 613-628	7.9	8
183	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019 , 11,	6.6	8
182	Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George Letter to the Editor re: Arnaud M Jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. <i>Eur Urol</i> 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. <i>Therapeutic Advances in Urology</i> , 2019 , 11, 1756287218815372	10.2	2
181	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019 , 11,	3.2	6
180	The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes. <i>Targeted Oncology</i> , 2019 , 14, 247-252	6.6	21
179	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. <i>Frontiers in Oncology</i> , 2019 , 9, 228	5	10
178	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019 , 11, 631-643	5.3	14
177	Microbiome and Cancers, With Focus on Genitourinary Tumors. <i>Frontiers in Oncology</i> , 2019 , 9, 178	3.8	21
176	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019 , 39, 503-519	5.3	10
175		3.2	23

174	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019 , 11,	6.6	20
173	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. <i>Cancers</i> , 2019 , 11,	6.6	15
172	BAP1 in solid tumors. <i>Future Oncology</i> , 2019 , 15, 2151-2162	3.6	17
171	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 142, 141-152	7	11
170	New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e871-e877	3.3	18
169	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End. <i>European Urology Oncology</i> , 2019 , 2, 103-104	6.7	1
168	Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019 , 7, 572	3.2	21
167	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. <i>Current Drug Metabolism</i> , 2019 , 20, 305-312	3.5	7
166	RISE-HEP project part 1: Treatment sequences evaluation in hepatocellular carcinoma cell lines.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15663-e15663	2.2	
165	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2019 , 12,	6.6	14
164	The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
163	Transient Receptor Potential Cation Channels in Cancer Therapy. <i>Medical Sciences (Basel, Switzerland)</i> , 2019 , 7,	3.3	14
162	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 917-927	2.5	2
161	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019 , 8,	7.9	20
160	Association among metabolic syndrome, inflammation, and survival in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 240.e1-240.e11	2.8	13
159	Immune checkpoint inhibitors for metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , 2018 , 64, 11-20	14.4	57
158	"Immuno-Transient Receptor Potential Ion Channels": The Role in Monocyte- and Macrophage-Mediated Inflammatory Responses. <i>Frontiers in Immunology</i> , 2018 , 9, 1273	8.4	32
157	Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. <i>Frontiers in Oncology</i> , 2018 , 8, 221	5.3	18

156	Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2018 , 13, e0197035	3.7	16
155	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , 2018 , 14, 2559-2564	3.6	5
154	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. <i>Cancer Treatment Reviews</i> , 2018 , 68, 80-85	14.4	18
153	Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors. <i>European Urology</i> , 2018 , 74, 521-522	10.2	21
152	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 645-655	3.8	13
151	Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018 , 1869, 78-84	11.2	82
150	High CTLA-4 expression correlates with poor prognosis in thymoma patients. <i>Oncotarget</i> , 2018 , 9, 16665-16671	3.5	16
149	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2018 , 10, 1303-1313	3.8	1
148	The Identification of Immunological Biomarkers in Kidney Cancers. <i>Frontiers in Oncology</i> , 2018 , 8, 456	5.3	32
147	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018 , 8, 397	5.3	15
146	Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2018 , 38, 5773-5782	2.3	10
145	Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 131, 1-6	7	5
144	Tivozanib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1021-1025	10.25	13
143	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. <i>World Journal of Urology</i> , 2017 , 35, 517-526	4	9
142	First-Line Pazopanib in Non-clear-cell Renal carcinoma: The Italian Retrospective Multicenter PANORAMA Study. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e609-e614	3.3	30
141	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 541.e7-541.e13	2.8	9
140	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. <i>European Urology Supplements</i> , 2017 , 16, 301-308	0.9	4
139	Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. <i>Oncology</i> , 2017 , 92, 269-275	3.6	3

138	Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach. <i>European Urology Supplements</i> , 2017 , 16, 309-315	0.9	7
137	Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035). <i>Cancer Treatment Reviews</i> , 2017 , 60, 12-17	14.4	12
136	Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. <i>Cancer Treatment Reviews</i> , 2017 , 59, 123-131	14.4	34
135	Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. <i>Oncotarget</i> , 2017 , 8, 23871-23879	3.3	29
134	Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. <i>Frontiers in Oncology</i> , 2017 , 7, 305	5.3	17
133	Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner. <i>Oncotarget</i> , 2017 , 8, 3380-3395	3.3	24
132	The TRPV1 ion channel regulates thymocyte differentiation by modulating autophagy and proteasome activity. <i>Oncotarget</i> , 2017 , 8, 90766-90780	3.3	14
131	Bone Homing and Metastasis 2017 , 25-32		
130	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. <i>European Urology</i> , 2016 , 69, 186-90	10.2	13
129	Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: Game Over . <i>Targeted Oncology</i> , 2016 , 11, 431-46	5	5
128	Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. <i>Cancer Treatment Reviews</i> , 2016 , 48, 20-4	14.4	90
127	Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 426-431	3.3	7
126	Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. <i>Archives of Pathology and Laboratory Medicine</i> , 2016 , 140, 501-2	5	10
125	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2016 , 11, 143-8	5	108
124	Transplantation of kidneys with tumors. <i>Journal of Nephrology</i> , 2016 , 29, 163-168	4.8	8
123	Prostate cancer: from Gleason scoring to prognostic grade grouping. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 433-40	3.5	16
122	Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 324-31	7	11
121	Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy. <i>Molecular Diagnosis and Therapy</i> , 2016 , 20, 111-7	4.5	57

120	Metabolic phenotype of bladder cancer. <i>Cancer Treatment Reviews</i> , 2016 , 45, 46-57	14.4	117
119	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , 2016 , 70, e72-4	10.2	5
118	Hyponatremia in cancer patients: Time for a new approach. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 102, 15-25	7	40
117	AR-V7 and prostate cancer: The watershed for treatment selection?. <i>Cancer Treatment Reviews</i> , 2016 , 43, 27-35	14.4	41
116	Capsaicin triggers autophagic cell survival which drives epithelial mesenchymal transition and chemoresistance in bladder cancer cells in an Hedgehog-dependent manner. <i>Oncotarget</i> , 2016 , 7, 50180-50194	3.3	41
115	Post-transcriptional regulation of 5' untranslated regions of human Transient Receptor Potential Vanilloid type-1 (TRPV-1) channels: role in the survival of glioma patients. <i>Oncotarget</i> , 2016 , 7, 81541-81554	3.3	12
114	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 33381-90	3.3	10
113	Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. <i>Oncotarget</i> , 2016 , 7, 26916-24	3.3	34
112	Overexpression of transient receptor potential mucolipin-2 ion channels in gliomas: role in tumor growth and progression. <i>Oncotarget</i> , 2016 , 7, 43654-43668	3.3	33
111	Metabolic Alterations in Renal and Prostate Cancer. <i>Current Drug Metabolism</i> , 2016 , 17, 150-5	3.5	13
110	An Overview of Emerging Immunotargets of Genitourinary Tumors. <i>Current Drug Targets</i> , 2016 , 17, 750-6	3	8
109	Emerging Immunotargets in Bladder Cancer. <i>Current Drug Targets</i> , 2016 , 17, 757-70	3	6
108	Emerging Immunotargets and Immunotherapies in Prostate Cancer. <i>Current Drug Targets</i> , 2016 , 17, 777-82	3	7
107	mTOR Pathway in Renal Cell Carcinoma 2016 , 417-428		
106	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2016 , 17, 771-6	3	12
105	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , 2016 , 7, 54564-54571	3.3	89
104	Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. <i>PLoS ONE</i> , 2016 , 11, e0152079	3.7	32
103	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016 , 11, e0151662	3.7	39

102	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. <i>BioDrugs</i> , 2016 , 30, 263-73	7.9	19
101	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. <i>Eur Urol</i> 2015;68:542-3. <i>European Urology</i> , 2016 , 70, e69-70	10.2	
100	Handling of the Surgical Specimen and Pathology Reporting of Penile Neoplasms 2016 , 275-280		
99	Handling of the Surgical Specimen and Pathology Reporting of Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis 2016 , 165-170		
98	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 10	12.8	50
97	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2094-100	3.1	48
96	Renal cancer in kidney transplanted patients. <i>Journal of Nephrology</i> , 2015 , 28, 659-68	4.8	24
95	Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report. <i>Human Pathology</i> , 2015 , 46, 1040-4	3.7	5
94	BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. <i>Expert Review of Molecular Diagnostics</i> , 2015 , 15, 1201-10	3.8	63
93	Metabolic alterations in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2015 , 41, 767-76	14.4	55
92	KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma. <i>Future Oncology</i> , 2015 , 11, 1905-17	3.6	6
91	Emerging drugs for the treatment of bone metastasis. <i>Expert Opinion on Emerging Drugs</i> , 2015 , 20, 637-517	5	
90	Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target. <i>Cancer Treatment Reviews</i> , 2015 , 41, 569-76	14.4	28
89	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015 , 10, 517-22	5	32
88	High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1377-84	3.1	66
87	Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. <i>International Journal of Cancer</i> , 2015 , 137, 1855-69	7.5	86
86	Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. <i>BMC Cancer</i> , 2015 , 15, 195	4.8	78
85	Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 113.e1-7	2.8	11

84	Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 809-24	5.9	34
83	Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?. <i>Future Oncology</i> , 2015 , 11, 107-19	3.6	11
82	Altering macrophage polarization in the tumor environment: the role of response gene to complement 32. <i>Cellular and Molecular Immunology</i> , 2015 , 12, 783-4	15.4	9
81	Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients. <i>Cellular and Molecular Immunology</i> , 2015 , 12, 122-4	15.4	2
80	Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Gr�berg, Lars Egevad. Tracking the Origin of Metastatic Prostate Cancer. <i>Eur Urol</i> 2015;67:819-22. <i>European Urology</i> , 2015 , 68, e134-5	10.2	3
79	Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 137-41	3.3	16
78	Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 244-9	3.3	10
77	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015 , 34, 765-73	9.6	28
76	Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 41-7	2.5	43
75	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2015 , 136, 1-10	7.5	41
74	Re: epithelial-to-mesenchymal transition in renal neoplasms. <i>European Urology</i> , 2015 , 68, 736-7	10.2	8
73	Danger- and pathogen-associated molecular patterns recognition by pattern-recognition receptors and ion channels of the transient receptor potential family triggers the inflammasome activation in immune cells and sensory neurons. <i>Journal of Neuroinflammation</i> , 2015 , 12, 21	10.1	89
72	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. <i>Future Oncology</i> , 2015 , 11, 3159-66	3.6	9
71	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2015 , 75, 1329-38	4.2	16
70	HER family receptor expression and prognosis in pancreatic cancer. <i>International Journal of Biological Markers</i> , 2015 , 30, e327-32	2.8	8
69	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2015 , 9, 263-7	1.2	6
68	Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. <i>Oncotarget</i> , 2015 , 6, 36245-59	3.3	38
67	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. <i>Cancer Treatment Reviews</i> , 2015 , 41, 614-22	14.4	18

66	Lgr5 expression, cancer stem cells and pancreatic cancer: results from biological and computational analyses. <i>Future Oncology</i> , 2015 , 11, 1037-45	3.6	8
65	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 303-9	2.8	12
64	Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 81-90	7	45
63	Present and future of personalized medicine in adult genitourinary tumors. <i>Future Oncology</i> , 2015 , 11, 1381-8	3.6	5
62	Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1367-9	3.5	16
61	Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , 2015 , 1, FSO15	2.7	39
60	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 206-19	7	20
59	Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature. <i>Current Urology Reports</i> , 2015 , 16, 3	2.9	11
58	Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 1905-10	2.5	9
57	The route to personalized medicine in bladder cancer: where do we stand?. <i>Targeted Oncology</i> , 2015 , 10, 325-36	5	13
56	PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. <i>Cancer Treatment Reviews</i> , 2015 , 41, 114-21	14.4	126
55	Chromium exposure and germinal embryonal carcinoma: first two cases and review of the literature. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2015 , 78, 1-6	3.2	16
54	Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15594-e15594	2.2	1
53	The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?. <i>PLoS ONE</i> , 2015 , 10, e0120427	3.7	8
52	Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. <i>Oncoscience</i> , 2015 , 2, 395-409	0.8	21
51	Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy. <i>Oncotarget</i> , 2015 , 6, 19305-15	3.3	12
50	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. <i>Oncotarget</i> , 2015 , 6, 32161-8	3.3	24
49	Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview. <i>Current Drug Targets</i> , 2015 , 16, 96-102	3	5

48	Bladder cancer: molecular determinants of personalized therapy. <i>Current Drug Targets</i> , 2015 , 16, 115-243		14
47	Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. <i>Cancer Treatment Reviews</i> , 2014 , 40, 495-506	14.4	10
46	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2014 , 135, 763-73	7.5	33
45	The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. <i>International Journal of Cancer</i> , 2014 , 134, 2534-46	7.5	65
44	Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. <i>Cancer Treatment Reviews</i> , 2014 , 40, 271-5	14.4	71
43	Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1845, 221-31	11.2	41
42	Resiniferatoxin induces death of bladder cancer cells associated with mitochondrial dysfunction and reduces tumor growth in a xenograft mouse model. <i>Chemico-Biological Interactions</i> , 2014 , 224, 128-35	5.5	11
41	Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 630-7	11.2	25
40	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 929-38	3.8	50
39	Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. <i>PLoS ONE</i> , 2014 , 9, e105268	3.7	25
38	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. <i>Canadian Urological Association Journal</i> , 2014 , 8, E121-5	1.2	7
37	Cross-talk between alpha1D-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation. <i>BMC Cancer</i> , 2014 , 14, 921	4.8	30
36	Neoadjuvant therapy in pancreatic cancer: an emerging strategy. <i>Gastroenterology Research and Practice</i> , 2014 , 2014, 183852	2	25
35	CXC and CC chemokines as angiogenic modulators in nonhaematological tumors. <i>BioMed Research International</i> , 2014 , 2014, 768758	3	43
34	Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 208-17	7	25
33	Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. <i>International Journal of Cancer</i> , 2014 , 134, 2772-7	7.5	47
32	Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize?. <i>Diagnostic Pathology</i> , 2014 , 9, 190	3	6
31	Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. <i>Pathology</i> , 2014 , 46, 653-5	1.6	10

30	Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression. <i>Cells</i> , 2014 , 3, 112-289	9.9	39
29	[¹¹¹ C]-methionine positron emission tomography in the postoperative imaging and followup of patients with primary and recurrent gliomas. <i>ISRN Oncology</i> , 2014 , 2014, 463152		7
28	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. <i>Cancer and Metastasis Reviews</i> , 2014 , 33, 321-31	9.6	21
27	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 471-477	7.7	7
26	Advances in transient receptor potential vanilloid-2 channel expression and function in tumor growth and progression. <i>Current Protein and Peptide Science</i> , 2014 , 15, 732-7	2.8	15
25	Epigenetic, Genetic, and Acquired Regulation of Cav3 T-Type Calcium Channel Expression and Function in Tumor Growth and Progression 2014 , 277-295		
24	Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013 , 113, 397-401	4.8	16
23	Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1757-68	7.4	92
22	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. <i>European Journal of Cancer</i> , 2013 , 49, 2134-42	7.5	55
21	Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 697-709	3.5	12
20	Progress of molecular targeted therapies for advanced renal cell carcinoma. <i>BioMed Research International</i> , 2013 , 2013, 419176	3	27
19	The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responses. <i>Frontiers in Immunology</i> , 2013 , 4, 34	8.4	54
18	Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. <i>Carcinogenesis</i> , 2013 , 34, 48-57	4.6	156
17	Oncogenic and anti-oncogenic effects of transient receptor potential channels. <i>Current Topics in Medicinal Chemistry</i> , 2013 , 13, 344-66	3	27
16	TRP channels: new potential therapeutic approaches in CNS neuropathies. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013 , 12, 274-93	2.6	24
15	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2013 , 6, 563-76	4.4	20
14	Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. <i>PLoS ONE</i> , 2013 , 8, e83026	3.7	52
13	Essential role of Gli proteins in glioblastoma multiforme. <i>Current Protein and Peptide Science</i> , 2013 , 14, 133-40	2.8	44

12	Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?. <i>Current Cancer Drug Targets</i> , 2013 , 13, 313-25	2.8	7
11	Expression and function of the transient receptor potential ion channel family in the hematologic malignancies. <i>Current Molecular Pharmacology</i> , 2013 , 6, 137-48	3.7	21
10	VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. <i>Anticancer Research</i> , 2013 , 33, 5017-22	2.3	11
9	Functional role of T-type calcium channels in tumour growth and progression: prospective in cancer therapy. <i>British Journal of Pharmacology</i> , 2012 , 166, 1244-6	8.6	46
8	A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy. <i>Journal of Translational Medicine</i> , 2012 , 10, 90	8.5	9
7	Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. <i>Oncology Letters</i> , 2012 , 4, 799-801	2.6	8
6	The transient receptor potential vanilloid-2 cation channel impairs glioblastoma stem-like cell proliferation and promotes differentiation. <i>International Journal of Cancer</i> , 2012 , 131, E1067-77	7.5	54
5	Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2012 , 7, 104-10	1.6	17
4	Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder. <i>Advances in Urology</i> , 2012 , 2012, 397412	1.6	19
3	Capsaicin promotes a more aggressive gene expression phenotype and invasiveness in null-TRPV1 urothelial cancer cells. <i>Carcinogenesis</i> , 2011 , 32, 686-94	4.6	51
2	New deals on the transcriptional and post-transcriptional regulation of TRP channel target genes during the angiogenesis of glioma. <i>Journal of Experimental and Integrative Medicine</i> , 2011 , 1, 221		5
1	TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. <i>Carcinogenesis</i> , 2010 , 31, 794-803	4.6	76